Stock Price Quote

IND-SWIFT LABORATORIES LTD.

NSE : INDSWFTLABBSE : 532305ISIN CODE : INE915B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE123.16-0.4 (-0.32 %)
PREV CLOSE ( ) 123.56
OPEN PRICE ( ) 124.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 28637
TODAY'S LOW / HIGH ( )122.44 125.05
52 WK LOW / HIGH ( )63.4 138.25
NSE123.10-0.65 (-0.53 %)
PREV CLOSE( ) 123.75
OPEN PRICE ( ) 124.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 432712
TODAY'S LOW / HIGH( ) 122.20 125.35
52 WK LOW / HIGH ( )63 138.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 04-01 1995
Management Info
N R Munjal - Chairman N R Munjal - Managing Director
Registered Office

Address S C O 850,Shivalik Enclave, N A C,Manimajra,
Chandigarh,
Union Territory-160101

Phone 0172 5061850 / 2730920

Email investor@indswiftlabs.com

Website www.indswiftlabs.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE, MCX

NEWS

19Apr Ind-Swift Laboratories informs about a
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligat..
19Apr Ind-Swift Laboratories to incorporate
Ind-Swift Laboratories has received approval to incorporate wholly owned..
19Apr Ind-Swift Laboratories rises on gettin
Ind-Swift Laboratories is currently trading at Rs. 116.66, up by 0.18 po..
04Apr Ind-Swift Laboratories informs about d
Ind-Swift Laboratories has informed that the exchange has received the d..
03Apr Ind-Swift Laboratories informs about d
Ind-Swift Laboratories has informed that the exchange has received the d..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit216.55424.710000000002
Gross Profit 267.47 791.970000000002
Operating Profit 613.572553.73
Net Sales 2762.8211519.57

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2621.00 (5.75%)
M.Cap ( in Cr)1619.26
Glaxosmithkline Phar (BSE)
peergroup  2079.80 (7.06%)
M.Cap ( in Cr)35233.07
TTK Healthcare (BSE)
peergroup  1591.35 (5.77%)
M.Cap ( in Cr)2248.63
Cipla (BSE)
peergroup  1398.80 (3.79%)
M.Cap ( in Cr)112938.41
Torrent Pharma (BSE)
peergroup  2685.00 (1.85%)
M.Cap ( in Cr)90872.60

Shareholding Pattern

NON-INSTITUTION 49.72%
PROMOTERS 42%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Ltd. was incorporated in the year 1995. Its today's share price is 123.16. Its current market capitalisation stands at Rs 727.71 Cr. In the latest quarter, company has reported Gross Sales of Rs. 11571.73 Cr and Total Income of Rs.11852.39 Cr. The company's management includes N R Munjal, N R Munjal, Sahil Munjal, Rishav Mehta, Rajinder Kumar Gupta, Ashwani Vig, Neerja Chathley, S P Sharma, Himanshu jain, Pardeep Verma.

It is listed on the BSE with a BSE Code of 532305 , NSE with an NSE Symbol of INDSWFTLAB and ISIN of INE915B01019. It's Registered office is at S C O 850,Shivalik Enclave, N A C,ManimajraChandigarh-160101, Union Territory. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Avishkar Singhal & Associates, Jain & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.